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Abstract
Childhood adrenocortical tumour (ACT) is not a common disease, but in southern Brazil the prevalence is 15
times higher than in other parts of the world. One hundred and thirty-seven patients have been identified and
followed by our group over the past four decades. Affected children are predominantly girls, with a female-to-male
ratio of 3.5:1 in patients below 4 years of age. Virilization alone (51.6%) or mixed with Cushing’s syndrome
(42.0%) was the predominant clinical picture observed in these patients. Tumours are unilateral, affecting both
glands equally. TP53 R337H germline mutations underlie most childhood ACTs in southern Brazil. Epidemiological
data from our casuistic studies revealed that this mutation has ~10% penetrance for ACT. Surgery is the definitive
treatment, and a complete resection should always be attempted. Although adjuvant chemotherapy has shown
some encouraging results, its influence on overall outcome is small. The survival rate is directly correlated to
tumour size; patients with small, completely excised tumours have survival rates close to 90%, whereas in those
patients with inoperable tumours and/or metastatic disease it is less than 10%. In the group of patients with
large, excisable tumours, half of them have an intermediate outcome. Recent molecular biology techniques
and genomic approaches may help us to better understand the pathogenesis of ACT, the risk of developing
a tumour when TP53 R337H is present, and to predict its outcome. An ongoing pilot study consisting of close
monitoring of healthy carriers of the TP53 R337H mutation – siblings and first-degree relatives of known affected
cases – aims at the early detection of ACTs and an improvement of the cure rate.
Introduction
Adrenocortical tumours (ACT) occur at all ages
and have a bimodal distribution with peaks of
incidence at around 5 years of age and in the 4th
and 5th decades of life [1, 2]. Childhood ACTs are
rare, with the annual worldwide incidence
around 0.34 per million children below the age of 15
[1, 3]. In the United States, Surveillance Epidemiology
and End Results (SEER) data from the National Cancer
Institute show that only about 0.2% of all childhood
malignancies are ACTs [4].
In southern Brazil (State of Paraná), the ACT
incidence is 4.2 per million in the age range of 0 – 15
years [5] with higher prevalence in 0 – 4-year-old girls
(Fig. 1). Over the last 40 years, more than 137 ACT
patients under 19 years of age have been admitted for
treatment in the Pediatric Endocrinology Unit of the
Department of Pediatrics in the Clinical Hospital of the
Federal University of Paraná, in Curitiba, Brazil. This
hospital is a tertiary referral centre for a population of
approximately 16 million people, 5 million of whom are
less than 15 years of age. It should be noted that at
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least 5 other hospitals in our state are referral centres
for childhood malignancies. In the neighbouring State
of São Paulo, Marigo et al. observed that childhood
ACTs accounted for 2.9% of solid tumours registered at
Santa Casa de Misericordia of São Paulo over a period
of 15 years, whereas in the London Hospital for Sick
Children, ACTs comprised only 0.8% [6]. Later on, other
groups in the State of São Paulo also reported a large
series of ACTs in children and adolescents [7-10]. 
The population in these two Brazilian states are
descendants of migrants from Portugal, Italy, Spain,
Germany, Poland, Ukraine, Japan and Africa – countries
where the incidence of ACTs is not increased – and
a minority of the native population. The sporadic
occurrence, absence of any clinical characteristics
consistent with genetic disorders (i.e. Beckwith-Wiedemann
and MEN1 syndromes, hemihypertrophy, congenital
adrenal hyperplasia and Carney complex) or familial
cancer history characteristic of Li-Fraumeni syndrome (LFS),
is a common feature of the majority of Brazilian children
with ACTs [5, 8-11]. 
Childhood ACT is often the first indicator of
a familial predisposition to cancer [12]. Typically,
germline mutations in these families were mapped to
the highly conserved DNA-binding domain of the TP53
gene (exons 5-8). However, some children who develop
ACTs in the absence of familial cancer syndromes
harbour germline mutations in other regions of TP53
[13]. Due to ACTs having a higher incidence in our
state and the absence of mutations in exons 5-9 of
TP53, all coding regions of the gene have been
examined. A germline mutation, R337H in exon 10 of
TP53, was identified in 35 of 36 patients studied [11].
Because Paraná and São Paulo have extensive
agricultural activities, it is tempting to speculate that
environmental pollutants, such as pesticides, may pose
a substantial health hazard and possibly contribute to
adrenal tumorigenesis in individuals with the TP53 R337H
mutations. Pesticides are widely used in Paraná without
any safety guidelines. Interestingly, British investigators
found an association between increased ACT incidence
and pesticide use in North West England [14]. Supportive
evidence is also forthcoming from Norway, where
Kristensen et al. reported an almost 2-fold increase in the
relative risk of cancer amongst 0–4-year-old children
whose parents were agricultural workers [15]. 
Biological aspects of adrenocortical tumour 
Whether adrenocortical carcinomas develop from
benign adenomas or are a separate disease remains
to be fully determined. In our experience, all ACT cases
clearly diagnosed as adenomas behaved benignly and
were stage I disease (see Table 1). Those tumours
associated with virilization (VS), Cushing’s syndrome
(CS), or mixed syndrome (MS – virilization and excess
Table 1. Staging criteria for childhood adrenocortical tumour (Sandrini et al. [5])
Stage Description
I tumour totally excised; tumour vol. <200 cm3, absence of metastasis, normal hormone levels after surgery
II microscopic residual tumour; tumour >200 cm3, tumour spillage during surgery or persistence 
of abnormal hormone levels after surgery

















Fig. 1. Distribution of 125 cases of childhood adrenocortical tumour
by age and gender
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of cortisol and/or mineralocorticoids) were
stage II tumours. Studies on tumour clonality aimed at
distinguishing carcinomas from adenomas have shown
disparate results [16, 17]. At one extreme end of the
spectrum, adrenocortical carcinomas are composed of
a monoclonal population of cells, whereas at the other
end, nodular hyperplasic adrenal tissue consists of
a polyclonal cell population. In between are adenomas,
where approximately half are monoclonal and half
polyclonal and/or mixed [17]. However, in another
study, almost all adenomas were monoclonal [16]. 
Several aspects of ACT formation are not well
understood at the present time, in particular the reasons
why some tumours are confined to certain dimensions
and secrete exclusively one type of steroid, while others
display more aggressive growth and metastasize and
co-secrete various types of hormones. 
In order to further understand adrenocortical
tumorigenesis several mechanisms were identified from
studies on rare genetic syndromes (reviewed in [18]),
such as multiple endocrine neoplasia type 1 (Menin gene
and locus 11q13), Carney complex (regulatory R1A
subunit of protein kinase A – PRKAR1A gene),
Beckwith-Wiedemann (IGF-II and 11p15 changes) and
McCune-Albright (GNAS1 gene) syndromes,
hemihypertrophy, congenital adrenal hyperplasia (CYP21
gene), glucocorticoid-remediable aldosteronism (hybrid
gene formed by CYP11B1 and CYP11B2 genes),
hereditary isolated glucocorticoid deficiency (MC2-R
gene) and alterations of the TP53 gene.
Further complexity of ACT tumorigenesis was
highlighted in a number of recent comparative genomic
hybridization (CGH) and microsatellite analysis studies
aimed at detecting chromosomal alterations. These
approaches identified alterations affecting various
chromosomes and loci (either losses or gains of part or
all of a chromosome) [17-21], both in adenomas and
carcinomas. CGH techniques demonstrated alterations
in 28% [17] to 61% [18] of adenomas. Sixty-two percent
of adrenal carcinomas showed losses in several
chromosomes [18, 20]. Also in carcinomas, studies using
microsatellite markers revealed loss of heterozygosity
(LOH)/allelic imbalance in almost all cases, at 11q13
(100%) and 2p16 (92%). Moreover, LOH at the 17p13
loci is highly specific to malignant tumours [18]. In 1999,
our group reported a consistent gain in number of copies
of chromosomal region 9q34 using CGH analysis [22]. 
More recently, gene expression profiling of ACT
samples using DNA microarray technology has revealed
previously unknown gene expression changes in ACTs
[23-26]. In addition, Figueiredo et al. demonstrated the
presence of high levels of DAX-1 transcripts and protein
expression and amplification of SF-1 in ACTs [27].
However, these findings did not correlate with clinical
manifestation of disease, such as tumour size, malignant
or benign behaviour, sex and age.
It is known that the IGF system is important in foetal
growth, and high expression of IGF-2, in concert with
ACTH, occurs in human foetal adrenal development
(reviewed in [28]). IGF-2 is also highly expressed
in 85% of ACTs [29-31]. In addition, other components
of the IGF system are defective in ACTs; for example,
over-expression of IGF binding protein 2 (IGFBP2) and
IGF type-1 receptor (IGF1R) proteins. IGF type-2
receptor (IGF2R) loss of function by inactivating
mutations located in the DNA coding region and LOH
at the IGF2R loci were reported in ACTs [32, 33].
Knowledge of normal adrenal cortex development and
linkage of ACTs to other genes, such as CDKN1C [34],
H19 [35], INHA [36], GATA-4 [37] and proteins such
as angiopoietin, urotensin II and novH (reviewed in
[28]), makes comprehension of the molecular events
underlying adrenocortical tumorigenesis very intricate. 
TP53 mutations and tumorigenesis 
Recent progress has been achieved in the
understanding of adrenocortical tumorigenesis by the
mapping and identification of genes associated with
hereditary adrenal gland tumours (reviewed in
[18, 38]). More generally, lesions either in the
machinery that senses DNA damage or in the
machinery that implements a response to DNA damage
greatly alters the likelihood of cancer. Mutation in the
tumour suppressor gene TP53 is a key mutational event
in over half of all human cancers, and mutations in
TP53 are the most frequently observed genetic change
in cancer [39]. The high frequency with which p53
protein is functionally inactivated in human cancers
indicates its pivotal role against the expansion of
a population of mutated somatic cells. In many cases,
TP53 itself is mutated or deleted [40, 41]. 
The p53 pathway responds to stresses that can
disrupt the fidelity of DNA replication and cell division.
Stress signals are transmitted to p53 proteins by
post-translational modification. This results in activation
of p53 protein as a transcription factor that initiates
a programme of cell cycle arrest, cellular senescence
or apoptosis. Which of these responses prevails seems
to depend on cell type, cell environment, and other
factors such as oncogene expression. Evidence
indicates that p53 induces growth arrest after certain
types of irreversible DNA damage; although alive, such
cells are genetically dead as they cannot contribute to
a daughter cell population and thus constitute no
further neoplastic risk [42-48]. The transcriptional
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network of p53-responsive genes produces proteins
that interact with a large number of other signal
transduction pathways in cells and a number of positive
and negative auto-regulatory feedback loops acting
upon the TP53 response [49].
p53 is a 393 amino acid protein containing several
functional domains: the activation domain 1 (AD1)
within residues 1 to 42, the activation-domain 2 (AD2)
within residues 43 to 63, the proline-rich domain (PRD)
within residues 64 to 91, the sequence-specific
DNA-binding-domain (DBD) within residues 100 to 300,
the nuclear localization signal within residues 316
to 325, the tetramerization-domain (TD) within
residues 334 to 356, and the C-terminal-basic-domain
(BD) within residues 364 to 393 [39, 50-53].
TP53 and paediatric ACT
The majority of TP53 germline mutations in cancer
are localized between exons 5 and 8, the highly
conserved DNA-binding-domain of the gene, although
mutations located in other regions have also been
described. Highly penetrant TP53 germline mutations
are identified in over 77% of families with Li-Fraumeni
syndrome (LFS), an autosomal dominant inherited
cancer syndrome characterized by the occurrence of
a variety of cancers diagnosed at young ages [54-58].
In patients with LFS, ACT accounts for 3% of all tumours
occurring at any age and for 10% of childhood ACTs
[13]. Thus, TP53 mutations appear to increase ACTs
predisposition in children. In North America and
Europe, 50–80% of children with apparently sporadic
ACTs carried TP53 germline mutations [13, 59]. 
Functional analysis of the TP53 germline mutation
described in patients from Paraná showed that in
contrast to TP53 R248W, the TP53 R337H mutant and
wild type TP53 were able to suppress colony growth of
SaOs-2 cells lacking endogenous p53. In addition, in
human H1299 lung carcinoma cells, which also lack
endogenous p53, ectopically expressed TP53 R337H
mutant was competent to induce apoptosis. Taken
together these data indicate that the R337H mutant
retains p53 activity at physiological conditions [11]. 
TP53 mutation and paediatric ACT 
in southern Brazil
TP53 R337H is present in 97% of all cases of
children with ACT treated in the State of Paraná [11].
The same mutation was reported occurring at
a prevalence of 75 and 77.7% by two independent
groups of investigators in the neighbouring State of
São Paulo [8, 9]. The mutation was also identified in 5
of 37 and in 1 of 5 adult patients studied by the latter
groups, respectively. Interestingly, adult patients who
tested positive for the mutation were all young (age
range 19 to 36 years).
Chompret et al. reported the same germline
mutation in a 4-yr-old girl with sporadic ACT [60].
Varley et al. analysed a panel of 14 cases of sporadic
childhood ACTs [13]. TP53 germline mutations were
identified in over 80% and in one case the TP53
R337H mutation was present in a tumour, with the
complete loss of the wild type allele; however, they
were unable to determine whether this mutation was
inherited or acquired.
Recently, DiGiammarino et al. were able to expose
subtle defects of the mutant protein while studying its
behaviour, in vitro, under variations in pH and
temperature [61]. From their study, it was shown that
tetramer formation of the R337H p53 mutant becomes
significantly less stable as pH increases toward the
physiological range between 7 and 8. A substantial
fraction of mutant p53 R337H variants remain unfolded
at pH 8 and at 37°C (>70% unfolded), whereas
wildtype p53 is fully folded under the same conditions
[61]. Previous to this study, Davison et al. using circular
dichroism spectroscopy were also able to show the
effects of temperature on the stability of the p53 mutant
protein in families with LFS and Li-Fraumeni like
syndrome with TP53 L344P and TP53 R337C
mutations, respectively, located in the tetradimerization
zone of TP53 [62]. The cause of the TP53 R337H
mutation is presently unknown. The demonstration of
different markers surrounding and within the mutated
TP53 gene in various unrelated subjects strongly
indicates that it is derived from diverse ancestors [11].
In contrast, Pinto et al. studied 22 patients (16 children
and 6 adults) from the State of São Paulo and
concluded that the TP53 R337H germline mutation
arose from a single common ancestor [63]. 
Several lines of evidence show that the TP53
R337H mutation is strongly related to ACT in children
in southern Brazil: a) the families do not have
a common ancestry; b) TP53 R337H is not a common
polymorphism among southern Brazilians; c) the loss
of heterozygosity with retention of the mutant allele in
the tumour cells, and d) the mutant p53 protein is
highly expressed in the ACTs [11, 64]. 
Over 927 individuals were tested for the TP53
R337H mutation, 232 from the non-carrier and 695
(including 40 probands) from the carrier parental line.
In the carrier parental line, the mutation tested positive
in 240 individuals (34.5%) and in none of the
non-carrier parental line [65]. In this group, fifty percent
of the parents and grandparents evaluated carried the
TP53 R337H mutation. Thus, there is no evidence of
de novo mutation. All probands carried the mutation
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in the heterozygous state in the series of cases from
Paraná. In the State of São Paulo, Latronico et al.
described one patient who was homozygous for the
mutation and whose parents both carried the mutation
in a heterozygous state [8].
The estimated penetrance of ACT among carriers of
the TP53 R337H mutation is 9.9% (95% CI, 8.7-11.1%)
and it is greater in the 8 kindreds with multiple cases
of ACT (12.5%; 95% CI, 10.2-14.6%) than in kindreds
with a single case (8.5%; 95% CI, 7.3-9.7%) [65].
Varley et al. had already described TP53 mutations
in 14 cases of childhood ACT with equally low cancer
penetrance [13].
Although the penetrance of this mutation is low, close
monitoring of children at risk of ACT is advisable in order
to detect the presence of tumour as early as possible,
thereby improving outcome. Relevant in this regard are
the data of Pereira et al., where 65 children (siblings and
first-degree relatives), 0.25 to 14.6 years of age and all
carriers of the TP53 R337H mutation, have been
followed for three consecutive years, on a clinical,
laboratory and imaging basis. There is currently no
evidence of ACT developing in these children. The aim
of the study is to follow these individuals for as long as
possible, in order to acquire more data to better define
the penetrance of this mutation [66].
Clinical features
We have conducted a comprehensive review of 125
patients from 137 who attended our service
between 1966 and December 2005.
Ninety patients were girls (72%); median age of the
entire group was 3.2 years, two thirds being aged 0-4
years (5 patients presented with an ACT at birth, Fig. 1).
The ratio of girls to boys was 2.6:1 for this group
and 3.5:1 in patients below 4 years. The mean time
interval between the appearance of the first clinical
signs and the diagnosis of disease was 11 months.
None of the patients had conspicuous African,
Brazilian, or Japanese ancestry. 
Virilization alone was present in 51.2% of patients;
virilization associated with Cushing’s syndrome (CS)
occurred in 42.4% of patients. One patient exhibited
pure CS while another displayed isolated hypertension.
Endocrine silent tumours comprised 4.8% of all
patients. Percentages of occurrence of the main clinical
signs (precocious puberty, clitoris or penis hypertrophy,
coarse voice, hypertension, facial hyperaemia, weight
gain, hirsutism, accelerated growth velocity, etc.) do not
differ much from those in a group of 58 children
studied by Sandrini et al. in 1997 [5].
Hypertension in the course of ACTs deserves special
attention, especially in those patients with mixed
syndromes (virilization and excess of cortisol and/or
mineralocorticoids). Not infrequently it is severe enough
to cause hypertensive encephalopathy with seizures.
Aggressive therapy with ECA inhibitors and furosemide
is routine in our service. After complete tumour removal
hypertension does not abate rapidly; indeed, in some
cases it persists for two to four weeks. The frequency of
palpable abdominal mass is less than that reported
in 1997, possibly due to increasing awareness, by
paediatricians, of the possibility of adrenal tumour in
young children with precocious puberty. Curiously, purple
striae occurred in only 2 patients, although
hypercortisolism was present in almost half of all patients.
Vena cava invasion, extending to the right atrium, is
usually associated with large and long-standing tumours;
it is rarely present in the course of small tumours. Both
glands were equally affected and concomitantly bilateral
ACT has never been recorded. However, a 3.5-yr-old-girl
who had a small tumour completely removed from the
left adrenal presented with a tumour in the right gland 12
years later, with pulmonary metastasis and vena cava
and right atrium invasion.
Diagnosis
At present, our routine hormonal profile for patients
suspected of having ACT includes measurements of
serum (8am, 11pm) cortisol, testosterone, DHEA-S,
androstenedione, 17-hydroxyprogesterone, aldosterone,
and PRA. 
Several different imaging techniques have been used
to confirm the presence of tumour, for staging the disease
and to help plan the surgical approach. Magnetic
resonance (MR), computerized tomography (CT) and
ultrasound (US) are used to confirm the presence of the
tumour, to visualize invasion of close structures (liver,
pancreas, kidney and diaphragm), metastasis and
venous invasion. However, it should be stressed that
depending on the equipment used, very small tumours
may be missed when investigated by US alone. All newly
diagnosed patients are scanned with CT to assess the
level of metastasis, if any, in the lung and liver, as these
are the most common sites of spread. Calcifications are
frequent and can present either as small focal inclusions
or extensive linear and amorphous deposits. Whole body
fluoro-deoxyglucose positron-emission tomographic
imaging (PET-SCAN) has been incorporated into the
diagnostic procedures of ACT [67, 68].
Treatment
Surgery
Complete resection of tumour and local lymph
nodes is the single most important procedure in
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successful treatment of ACT. En bloc resection, which
may include the adjacent structures invaded by the
tumour, is required in cases of large and invasive
tumours. Due to the friability of the tumour, rupture of
the capsule and tumour spillage can occur. 
A hundred and twenty-three out of 125 patients
have been operated on. In 86.2% of the cases the
tumour was completely excised; in 10.6% the tumour
was inoperable and in 3.2% only partial resection was
performed. 
Venous tumour invasion, especially of the vena cava,
occurred in 19.6% of 92 patients in which it was carefully
searched for. US, MR and cavography have been used
to look for the presence of venous invasion. In cases
where the tumour invades the right atrium the
concurrence of a cardiovascular surgeon is mandatory.
In such cases, extracorporeal circulation is recommended. 
Surgical resection is also indicated for recurrent local
disease or metastases. Multiple surgical interventions
may be needed for recurrence, providing prolonged
survival or even cure. One patient is free of disease 20
yrs after being operated on twice for tumour bed
recurrence and once for hepatic metastases. 
Chemotherapy
Chemotherapy has been used to treat metastatic
ACT and for those cases of large inoperable or partially
excised tumour and for recurrences. Despite the use
of different protocols of chemotherapeutic agents, none
has emerged that has been shown to be sufficiently
effective to be widely adopted. Mitotane has been used
since the 1960s, initially for adult patients [69]. It
inhibits adrenocortical hormone biosynthesis and
causes destruction of adrenal cells [70]. While low
doses (<3 g/day) suppress steroid synthesis and
regression of clinical signs, with higher doses (>3
g/day) an adrenolytic effect is observed. It should be
stressed that no correlation exists between suppressed
steroid synthesis and tumour regression [71]. After years
of enthusiasm for mitotane that peaked during the
mid-1980s, subsequent large trials showed transient
partial responses and no complete responses [70].
Despite objective response to mitotane observed in
some patients, the survival rate was not significantly
increased [72]. A clinical trial with mitotane conducted
in our service included 10 consecutive children with
stages II and III disease. Only a single patient with an
inoperable tumour had a partial response, which
permitted curative surgery; the patient has been
disease-free for the last 16 yrs (unpublished data).
Based on the experience of Berruti et al., who showed
favourable results with a combination of mitotane with
cisplatin, etoposide, and doxorubicin, we have adopted
this scheme with a lower dose of mitotane [66, 73].
Notwithstanding, low doses of mitotane produced side
effects in a sizable proportion of patients, which
included mainly nausea, vomiting, anorexia and mood
changes. Despite the observation of complete
remission of metastasis, the time of observation and
the limited number of patients so far treated do not
permit us to draw any firm conclusions [66]. Paediatric
endocrinologists must have in mind the drawbacks
derived from mitotane use and therefore patients
should be followed closely. For instance, in order to
avoid adrenal insufficiency double to triple doses of
glucocorticoids and mineralocorticoids are needed.
Prognosis 
Because of the heterogeneity and rarity of ACTs,
prognostic factors have been difficult to establish.
The diagnosis of ACT is made on the basis of gross
and histological appearance of tissue obtained at
surgery. Classification of ACT as having a malignant
or benign potential based only on histopathology is
difficult [5]. However, all 20 patients from our
personal experience who have received the diagnosis
of adenoma are still alive.
Due to difficulties in correlating the histopathological
findings to ACT prognosis, clinical characteristics,
laboratory profile, therapeutic approach and presence
or absence of metastasis were evaluated in relation to
outcome. A multivariate analysis showed that only
tumour size was significantly associated with survival [5].
Subsequently, data of the International Pediatric
Adrenocortical Tumor Registry (IPACTR), based on the
evaluation of 254 patients, 43.4% of whom were from
our service and 36.0% from other Brazilian centres,
showed that tumour stage I (Table 1), virilization alone
and age 0 – <4 years, were significantly related to
greater probability of event-free survival [5, 74]. On the
other hand, incomplete tumour excision, capsule rupture
during surgery and presence of intravenous thrombi were
linked to a bad prognosis.
Concluding remarks
Several characterized TP53 polymorphisms showed
altered regulation of p53 protein post-translational
modifications, protein stability, nuclear localization and
downstream signalling. Restoration of TP53 functions,
in particular TP53-dependent apoptosis, is an attractive
cancer therapeutic strategy. To exploit TP53-dependent
apoptosis for the destruction of cancer cells, many
studies have focused on strategies that preferentially
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activate TP53 to induce proapoptotic target genes. It is
already known that there is great heterogeneity of p53
responsiveness among different tissues and during
different stages of development. Thus, it appears that
the regulation of p53 responsiveness plays an important
role not only in cancer but also during embryogenesis
and in normal tissue physiology. Therefore any individual
who has poor p53 responsiveness to DNA damaging
agents in internal tissues may be at a higher risk of
developing cancer in these tissues. Two distinct prognostic
groups of patients with ACT can be recognized: one with
very poor prognosis (patients with metastatic disease or
gross residual tumour) and one with a very good
prognosis (patients with completely excised tumour of
small size or adenoma histology). It would be of great
interest to identify additional prognostic molecular
markers within poor p53 responders more susceptible
to ACT and possibly combine cancer-preventive therapies
aimed at modulating TP53 activity to induce apoptosis
in tumour cells. More importantly, future studies should
delineate more complex genotypes associated with p53
mutations, novel elements in p53 cellular response and
deregulated cellular processes in ACT. Indeed, recent
molecular biology techniques and genomic approaches
have identified key cellular processes fundamental for
tumour development and progression.
Many questions remain unexplained in childhood
ACTs: a) Why is only one adrenal gland affected? b)
Could the hormonal milieu (oestriol during foetal growth
and oestradiol in the first two years of life) underlie sex
differences observed in ACT occurrence? c) Do cells
from the adrenal cortex foetal zone escape apoptosis by
the concerted action of several genes and gene products,
making them susceptible to tumorigenesis? d) What
endogenous and environmental factors determine
tumour behaviour? e) Will prospective studies of patients
and relatives with TP53 R337H mutation show whether,
in the longer term, ACT can appear in the contra-lateral
gland or play a role in other types of tumour?
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